<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36755365</PMID><DateCompleted><Year>2023</Year><Month>02</Month><Day>10</Day></DateCompleted><DateRevised><Year>2023</Year><Month>02</Month><Day>27</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">2053-8790</ISSN><JournalIssue CitedMedium="Print"><Volume>9</Volume><Issue>1</Issue><PubDate><Year>2022</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Lupus science &amp; medicine</Title><ISOAbbreviation>Lupus Sci Med</ISOAbbreviation></Journal><ArticleTitle>Erythrocyte complement receptor 1 (ECR1) and erythrocyte-bound C4d (EC4d) in the prediction of poor pregnancy outcomes in systemic lupus erythematosus (SLE).</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">e000754</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1136/lupus-2022-000754</ELocationID><Abstract><AbstractText Label="BACKGROUND">Complement activation has been associated with adverse pregnancy outcomes (APO) in SLE. Pregnant women with SLE were studied to evaluate whether complement dysregulation within the first two pregnancy trimesters predicts APO.</AbstractText><AbstractText Label="METHODS">Pregnant women fulfilled classification criteria for SLE. APO included neonatal death, preterm delivery before 36 weeks and small for gestational age newborn. Pre-eclampsia was also evaluated. Erythrocyte complement receptor 1 (ECR1) and erythrocyte-bound C4d (EC4d) were measured by flow cytometry. Complement proteins C3 and C4 were measured by immunoturbidimetry and anti-double-stranded DNA by ELISA in serum. Statistical analysis consisted of t-test, confusion matrix-derived diagnostic analysis, and multivariate logistic regression.</AbstractText><AbstractText Label="RESULTS">Fifty-one women had 57 pregnancies and 169 visits during the study. Baseline visits occurred mainly in the first (n=32) and second trimester (n=21). Fourteen (24.6%) pregnancies resulted in 21 APO with preterm delivery being the most common (n=10). ECR1 &lt;5.5&#x2009;net mean fluorescence intensity in the first trimester predicted APO with a diagnostic OR (DOR) of 18.33 (95% CI: 2.39 to 140.4; t-test p=0.04). Other individual biomarkers did not reach statistical significance. To estimate the likelihood of APO, we developed an algorithm that included the week of pregnancy, ECR1 and EC4d. From this algorithm, a Pregnancy Adversity Index (PAI) was calculated, and a PAI &gt;0 indicated an elevated likelihood of pregnancy complications (DOR: 20.0 (95% CI: 3.64 to 109.97)).</AbstractText><AbstractText Label="CONCLUSIONS">Low levels of ECR1 in early or mid-pregnancy are predictive of an APO. Incorporating the weeks of gestation and both ECR1 and EC4d generated a PAI, which further predicted serious pregnancy complications.</AbstractText><CopyrightInformation>&#xa9; Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Conklin</LastName><ForeName>John</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Exagen Inc, Vista, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Golpanian</LastName><ForeName>Michael</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Division of Rheumatology, New York University School of Medicine, New York, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Engel</LastName><ForeName>Alexis</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Division of Rheumatology, New York University School of Medicine, New York, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Izmirly</LastName><ForeName>Peter</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Division of Rheumatology, New York University School of Medicine, New York, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Belmont</LastName><ForeName>H Michael</ForeName><Initials>HM</Initials><AffiliationInfo><Affiliation>Division of Rheumatology, New York University School of Medicine, New York, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dervieux</LastName><ForeName>Thierry</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0002-3799-4438</Identifier><AffiliationInfo><Affiliation>Research and Development, Prometheus Laboratories, San Diego, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Buyon</LastName><ForeName>Jill P</ForeName><Initials>JP</Initials><Identifier Source="ORCID">0000-0002-3852-7129</Identifier><AffiliationInfo><Affiliation>Division of Rheumatology, New York University School of Medicine, New York, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alexander</LastName><ForeName>Roberta Vezza</ForeName><Initials>RV</Initials><Identifier Source="ORCID">0000-0001-8827-8637</Identifier><AffiliationInfo><Affiliation>Exagen Inc, Vista, California, USA ralexander@exagen.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Lupus Sci Med</MedlineTA><NlmUniqueID>101633705</NlmUniqueID><ISSNLinking>2053-8790</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D003176">Complement C3</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011951">Receptors, Complement</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D007231" MajorTopicYN="N">Infant, Newborn</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011247" MajorTopicYN="N">Pregnancy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011256" MajorTopicYN="N">Pregnancy Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008180" MajorTopicYN="Y">Lupus Erythematosus, Systemic</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D047928" MajorTopicYN="Y">Premature Birth</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004912" MajorTopicYN="N">Erythrocytes</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011248" MajorTopicYN="Y">Pregnancy Complications</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003176" MajorTopicYN="N">Complement C3</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011951" MajorTopicYN="N">Receptors, Complement</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">autoimmune diseases</Keyword><Keyword MajorTopicYN="N">autoimmunity</Keyword><Keyword MajorTopicYN="N">lupus erythematosus, systemic</Keyword></KeywordList><CoiStatement>Competing interests: JC and RVA are employees and stockholders of Exagen. TD is a stockholder of Exagen.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>6</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>8</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>2</Month><Day>9</Day><Hour>0</Hour><Minute>27</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>2</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>2</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36755365</ArticleId><ArticleId IdType="pmc">PMC9445792</ArticleId><ArticleId IdType="doi">10.1136/lupus-2022-000754</ArticleId><ArticleId IdType="pii">9/1/e000754</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Kaul A, Gordon C, Crow MK, et al. . Systemic lupus erythematosus. Nat Rev Dis Prim 2016;2:16039. 10.1038/nrdp.2016.39</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrdp.2016.39</ArticleId><ArticleId IdType="pubmed">27306639</ArticleId></ArticleIdList></Reference><Reference><Citation>Buyon JP, Kim MY, Guerra MM. Predictors of pregnancy outcome in prospective, multiethnic cohort of lupus patients. Ann Intern Med 2015;163:153&#x2013;63. 10.7326/M14-2235</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/M14-2235</ArticleId><ArticleId IdType="pmc">PMC5113288</ArticleId><ArticleId IdType="pubmed">26098843</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim MY, Guerra MM, Kaplowitz E, et al. . Complement activation predicts adverse pregnancy outcome in patients with systemic lupus erythematosus and/or antiphospholipid antibodies. Ann Rheum Dis 2018;77:549&#x2013;55. 10.1136/annrheumdis-2017-212224</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2017-212224</ArticleId><ArticleId IdType="pmc">PMC6037302</ArticleId><ArticleId IdType="pubmed">29371202</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen D, Buurma A, Goemaere NN, et al. . Classical complement activation as a footprint for murine and human antiphospholipid antibody-induced fetal loss. J Pathol 2011;225:502&#x2013;11. 10.1002/path.2893</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/path.2893</ArticleId><ArticleId IdType="pubmed">21688269</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramsey-Goldman R, Li J, Dervieux T, et al. . Cell-bound complement activation products in SLE. Lupus Sci Med 2017;4:e000236. 10.1136/lupus-2017-000236</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/lupus-2017-000236</ArticleId><ArticleId IdType="pmc">PMC5704741</ArticleId><ArticleId IdType="pubmed">29214038</ArticleId></ArticleIdList></Reference><Reference><Citation>Weinstein A. Cell-bound complement activation products are superior to serum complement C3 and C4 levels to detect complement activation in systemic lupus erythematosus: Comment on the article by Aringer et al. Arthritis Rheumatol 2020;72:860. 10.1002/art.41227</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.41227</ArticleId><ArticleId IdType="pubmed">32067409</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahearn JM, Liu C-C, Manzi S. Cell-bound complement activation products as lupus biomarkers: diagnosis, monitoring and stratification. Expert Rev Clin Immunol 2017;13:1133&#x2013;42. 10.1080/1744666X.2017.1392238</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/1744666X.2017.1392238</ArticleId><ArticleId IdType="pubmed">29025354</ArticleId></ArticleIdList></Reference><Reference><Citation>Dervieux T, Conklin J, Ligayon J-A, et al. . Validation of a multi-analyte panel with cell-bound complement activation products for systemic lupus erythematosus. J Immunol Methods 2017;446:54&#x2013;9. 10.1016/j.jim.2017.04.001</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jim.2017.04.001</ArticleId><ArticleId IdType="pubmed">28389175</ArticleId></ArticleIdList></Reference><Reference><Citation>Putterman C, Furie R, Ramsey-Goldman R, et al. . Cell-bound complement activation products in systemic lupus erythematosus: comparison with anti-double-stranded DNA and standard complement measurements. Lupus Sci Med 2014;1:e000056. 10.1136/lupus-2014-000056</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/lupus-2014-000056</ArticleId><ArticleId IdType="pmc">PMC4225732</ArticleId><ArticleId IdType="pubmed">25396070</ArticleId></ArticleIdList></Reference><Reference><Citation>Petri MA, Conklin J, O'Malley T, et al. . Platelet-bound C4d, low C3 and lupus anticoagulant associate with thrombosis in SLE. Lupus Sci Med 2019;6:e000318. 10.1136/lupus-2019-000318</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/lupus-2019-000318</ArticleId><ArticleId IdType="pmc">PMC6519690</ArticleId><ArticleId IdType="pubmed">31168401</ArticleId></ArticleIdList></Reference><Reference><Citation>Merrill JT, Petri MA, Buyon J, et al. . Erythrocyte-bound C4d in combination with complement and autoantibody status for the monitoring of SLE. Lupus Sci Med 2018;5:e000263. 10.1136/lupus-2018-000263</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/lupus-2018-000263</ArticleId><ArticleId IdType="pmc">PMC5976122</ArticleId><ArticleId IdType="pubmed">29868177</ArticleId></ArticleIdList></Reference><Reference><Citation>Gartshteyn Y, Mor A, Shimbo D, et al. . Platelet bound complement split product (PC4d) is a marker of platelet activation and arterial vascular events in systemic lupus erythematosus. Clin Immunol 2021;228:108755. 10.1016/j.clim.2021.108755</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clim.2021.108755</ArticleId><ArticleId IdType="pmc">PMC8252918</ArticleId><ArticleId IdType="pubmed">33984497</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramsey-Goldman R, Alexander RV, Massarotti EM, et al. . Complement activation in patients with probable systemic lupus erythematosus and ability to predict progression to American College of rheumatology-classified systemic lupus erythematosus. Arthritis Rheumatol 2020;72:78&#x2013;88. 10.1002/art.41093</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.41093</ArticleId><ArticleId IdType="pmc">PMC6972605</ArticleId><ArticleId IdType="pubmed">31469249</ArticleId></ArticleIdList></Reference><Reference><Citation>Svenungsson E, Gustafsson JT, Grosso G, et al. . Complement deposition, C4d, on platelets is associated with vascular events in systemic lupus erythematosus. Rheumatology 2020;59:3264&#x2013;74. 10.1093/rheumatology/keaa092</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/keaa092</ArticleId><ArticleId IdType="pmc">PMC7590416</ArticleId><ArticleId IdType="pubmed">32259250</ArticleId></ArticleIdList></Reference><Reference><Citation>Hochberg MC. Updating the American College of rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis &amp; Rheumatism 1997;40:1725. 10.1002/art.1780400928</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.1780400928</ArticleId><ArticleId IdType="pubmed">9324032</ArticleId></ArticleIdList></Reference><Reference><Citation>Petri M, Orbai A-M, Alarc&#xf3;n GS, et al. . Derivation and validation of the systemic lupus international collaborating clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum 2012;64:2677&#x2013;86. 10.1002/art.34473</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.34473</ArticleId><ArticleId IdType="pmc">PMC3409311</ArticleId><ArticleId IdType="pubmed">22553077</ArticleId></ArticleIdList></Reference><Reference><Citation>Buyon JP, Kalunian KC, Ramsey-Goldman R, et al. . Assessing disease activity in SLE patients during pregnancy. Lupus 1999;8:677&#x2013;84. 10.1191/096120399680411272</Citation><ArticleIdList><ArticleId IdType="doi">10.1191/096120399680411272</ArticleId><ArticleId IdType="pubmed">10568906</ArticleId></ArticleIdList></Reference><Reference><Citation>Franklyn K, Lau CS, Navarra SV, et al. . Definition and initial validation of a lupus low disease activity state (LLDAS). Ann Rheum Dis 2016;75:1615&#x2013;21. 10.1136/annrheumdis-2015-207726</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2015-207726</ArticleId><ArticleId IdType="pubmed">26458737</ArticleId></ArticleIdList></Reference><Reference><Citation>ACOG Committee on Obstetric Practice . ACOG pactice bulletin #33: diagnosis and management of preeclampsia and eclampsia. Int J Gynecol Obstet 2002;77:67&#x2013;75.</Citation><ArticleIdList><ArticleId IdType="pubmed">12094777</ArticleId></ArticleIdList></Reference><Reference><Citation>Robin X, Turck N, Hainard A, et al. . pROC: an open-source package for R and S+ to analyze and compare ROC curves. BMC Bioinformatics 2011;12:1&#x2013;8. 10.1186/1471-2105-12-77</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2105-12-77</ArticleId><ArticleId IdType="pmc">PMC3068975</ArticleId><ArticleId IdType="pubmed">21414208</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim J-W, Jung J-Y, Kim H-A, et al. . Lupus low disease activity state achievement is important for reducing adverse outcomes in pregnant patients with systemic lupus erythematosus. J Rheumatol 2021;48:707&#x2013;16. 10.3899/jrheum.200802</Citation><ArticleIdList><ArticleId IdType="doi">10.3899/jrheum.200802</ArticleId><ArticleId IdType="pubmed">33060317</ArticleId></ArticleIdList></Reference><Reference><Citation>Buyon J, Furie R, Putterman C, et al. . Reduction in erythrocyte-bound complement activation products and titres of anti-C1q antibodies associate with clinical improvement in systemic lupus erythematosus. Lupus Sci Med 2016;3:e000165. 10.1136/lupus-2016-000165</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/lupus-2016-000165</ArticleId><ArticleId IdType="pmc">PMC5051407</ArticleId><ArticleId IdType="pubmed">27752336</ArticleId></ArticleIdList></Reference><Reference><Citation>Khera R, Das N. Complement receptor 1: disease associations and therapeutic implications. Mol Immunol 2009;46:761&#x2013;72. 10.1016/j.molimm.2008.09.026</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.molimm.2008.09.026</ArticleId><ArticleId IdType="pmc">PMC7125513</ArticleId><ArticleId IdType="pubmed">19004497</ArticleId></ArticleIdList></Reference><Reference><Citation>Thielen AJF, Zeerleder S, Wouters D. Consequences of dysregulated complement regulators on red blood cells. Blood Rev 2018;32:280&#x2013;8. 10.1016/j.blre.2018.01.003</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.blre.2018.01.003</ArticleId><ArticleId IdType="pubmed">29397262</ArticleId></ArticleIdList></Reference><Reference><Citation>Kavai M. Immune complex clearance by complement receptor type 1 in SLE. Autoimmun Rev 2008;8:160&#x2013;4. 10.1016/j.autrev.2008.06.002</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.autrev.2008.06.002</ArticleId><ArticleId IdType="pubmed">18602499</ArticleId></ArticleIdList></Reference><Reference><Citation>Feinberg BB, Jack RM, Mok SC, et al. . Low erythrocyte complement receptor type 1 (CR1, CD35) expression in preeclamptic gestations. Am J Reprod Immunol 2005;54:352&#x2013;7. 10.1111/j.1600-0897.2005.00318.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1600-0897.2005.00318.x</ArticleId><ArticleId IdType="pubmed">16305660</ArticleId></ArticleIdList></Reference><Reference><Citation>Ross GD, Yount WJ, Walport MJ, et al. . Disease-associated loss of erythrocyte complement receptors (CR1, C3b receptors) in patients with systemic lupus erythematosus and other diseases involving autoantibodies and/or complement activation. J Immunol 1985;135:2005&#x2013;14.</Citation><ArticleIdList><ArticleId IdType="pubmed">4020137</ArticleId></ArticleIdList></Reference><Reference><Citation>Lea&#xf1;os-Miranda A, Campos-Galicia I, Berumen-Lechuga MG, et al. . Circulating angiogenic factors and the risk of preeclampsia in systemic lupus erythematosus pregnancies. J Rheumatol 2015;42:1141&#x2013;9. 10.3899/jrheum.141571</Citation><ArticleIdList><ArticleId IdType="doi">10.3899/jrheum.141571</ArticleId><ArticleId IdType="pubmed">25979720</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim MY, Buyon JP, Guerra MM, et al. . Angiogenic factor imbalance early in pregnancy predicts adverse outcomes in patients with lupus and antiphospholipid antibodies: results of the PROMISSE study. Am J Obstet Gynecol 2016;214:108.e1&#x2013;108.e14. 10.1016/j.ajog.2015.09.066</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ajog.2015.09.066</ArticleId><ArticleId IdType="pmc">PMC4698098</ArticleId><ArticleId IdType="pubmed">26432463</ArticleId></ArticleIdList></Reference><Reference><Citation>de Jes&#xfa;s GR, Lacerda MI, Rodrigues BC, et al. . Soluble Flt-1, placental growth factor, and vascular endothelial growth factor serum levels to differentiate between active lupus nephritis during pregnancy and preeclampsia. Arthritis Care Res 2021;73:717&#x2013;21. 10.1002/acr.24360</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acr.24360</ArticleId><ArticleId IdType="pubmed">32583963</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>